During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Rajat Bannerji, Rutgers Cancer Institute of New Jersey, New Brunswick, US. We asked, Is odronextamab a feasible option for patients with NHL who are refractory to CAR T-cell therapy?
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Is odronextamab a feasible option for patients with NHL who are refractory to CAR T-cell therapy?
Is odronextamab a feasible option for patients with NHL who are refractory to CAR T-cell therapy?
Bannerji talks about the updated data, presented at ASH 2020, on the bispecific antibody odronextamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
More about...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox